Analgesia AI
AI platform built on proprietary human pain data with a first clinically validated non-opioid drug to generate new pain therapeutics.
AnalgesiaAI is an AI tech-pharma company developing non-opioid topical pain drugs from proprietary human pain data. Its lead asset, AAI-201, is a clinically validated 12-hour topical therapy with human clinical evidence and a differentiated path in one of the largest pain-treatment markets.
AAI-201 is the first value driver. It gives AnalgesiaAI a validated drug asset, protected intellectual property, and a focused development path toward the next major clinical milestone. The company begins with clinical proof and builds from there.
The platform expands the upside. AnalgesiaAI is building an AI drug-development engine trained on its own first-party patient dataset, created through years of real-world pain treatment. This gives the company a proprietary data advantage directly tied to topical pain-drug creation.
The model is built for a pipeline. AAI-201 anchors the company, while the platform is designed to generate additional topical therapies across chronic pain, post-surgical pain, neuropathy, joint pain, and wound care. One validated asset creates the entry point; the platform creates repeatable drug output.
AnalgesiaAI gives investors a focused opportunity in non-opioid pain therapeutics: clinical validation, proprietary data, protected IP, AI-enabled drug creation, and a scalable topical pain pipeline. AAI-201 leads the company into the market. The platform gives it category-level upside.
Fundraise Details
This section is only visible to registered investors. Log in or register as an accredited investor to view.
Ready to Ask For Funding for your company?
Post a Funding RequestKey Facts
- Industry
- {{model.industry | ffIndustry}}
- Location
- {{model.city_state}}
- Year Founded
- {{model.year_founded}}
- Monthly Income
- {{model.monthly_income | ffIncome}}
- Website
- {{model.homepage_url}}